United Therapeutics R&D decreased by 0.9% to $138.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.2%, from $149.00M to $138.20M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 0.5% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $74.30M | $79.20M | $82.90M | $69.00M | $93.90M | $66.10M | $93.90M | $82.90M | $89.00M | $84.70M | $151.40M | $104.10M | $139.60M | $103.50M | $133.80M | $149.00M | $134.00M | $127.50M | $139.50M | $138.20M |
| QoQ Change | — | +6.6% | +4.7% | -16.8% | +36.1% | -29.6% | +42.1% | -11.7% | +7.4% | -4.8% | +78.7% | -31.2% | +34.1% | -25.9% | +29.3% | +11.4% | -10.1% | -4.9% | +9.4% | -0.9% |
| YoY Change | — | — | — | — | +26.4% | -16.5% | +13.3% | +20.1% | -5.2% | +28.1% | +61.2% | +25.6% | +56.9% | +22.2% | -11.6% | +43.1% | -4.0% | +23.2% | +4.3% | -7.2% |
Range$66.10M – $151.40M
CAGR+14.0%
Avg YoY Growth+17.5%
Median YoY Growth+21.2%
R&D at Other Companies
Frequently Asked Questions
- What is United Therapeutics's r&d?
- United Therapeutics (UTHR) reported r&d of $138.20M in Q1 2026.
- How has United Therapeutics's r&d changed year-over-year?
- United Therapeutics's r&d decreased by 7.2% year-over-year, from $149.00M to $138.20M.
- What is the long-term trend for United Therapeutics's r&d?
- Over 4 years (2021 to 2025), United Therapeutics's r&d has grown at a 0.5% compound annual growth rate (CAGR), from $540.10M to $550.00M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.